A crystalline form of nilotinib L-tartrate selected from: a) Crystalline Form I of nilotinib L-tartrate, characterized by data selected from among: a powder X-ray diffraction pattern that has peaks at 9, 4, 11.7, 12.7, 18.2 and 19.0 degrees two theta ± 0.2 degrees two theta or a powder X-ray diffraction pattern substantially as depicted in Figure 5； b) Crystalline Form II of nilotinib L-tartrate, characterized by data selected from: a powder X-ray diffraction pattern that has peaks at 8.7, 15.7, 17.2, 19.4 and 20.0 degrees two theta ± 0.2 degrees two theta or a powder X-ray diffraction pattern substantially as depicted in Figure 6； c) Crystalline Form III of nilotinib L-tartrate, characterized by data selected from: a powder X-ray diffraction pattern that has peaks at 8.2, 9.1, 12.3, 15.0 and 17.6 degrees two theta ± 0.2 degrees two theta or a powder X-ray diffraction pattern substantially as depicted in Figure 7； d) Crystalline Form IV of nilotinib L-tartrate, characterized by data selected from: a powder X-ray diffraction pattern that has peaks at 13.6, 18.3, 19.5, 21.9 and 24.3 degrees two theta ± 0.2 degrees two theta or a powder X-ray diffraction pattern substantially as depicted in Figure 8； e) Crystalline Form V of nilotinib L-tartrate, characterized by data selected from: a powder X-ray diffraction pattern that has peaks at 3.6, 7.6, 14.1, 17.8 and 19.5 degrees two theta ± 0.2 degrees two theta or a powder X-ray diffraction pattern substantially as shown in Figure 9 and f) Crystal Form VI of nilotinib L-tartrate, characterized by selected data of between: a powder X-ray diffraction pattern that has peaks at 4.7, 12.1, 16.3, 21.0 and 24.4 degrees two theta ± 0.2 degrees two theta or a pattern of X-ray powder diffraction substantially as depicted in Figure 10.Una forma cristalina del L-tartrato de nilotinib seleccionada de entre: a) la Forma Cristalina I del L-tartrato de nilotinib, caracterizada por unos datos seleccionados de entre: un patrón de difracción d
